Table 1 Summary of the different ex vivo models of GBM
From: Cerebral organoids: emerging ex vivo humanoid models of glioblastoma
Model type | Pros | Cons | References |
|---|---|---|---|
| Better captures clinical characteristics | Inconsistency during fusion process | |
More genetically diverse | Preparing of GSCs outside of tumor microenvironment | ||
Two distinct populations that can be isolated/studied | Limited availability of primary cell lines | ||
More amenable to optimization | Not applicable for studying tumor initiation events | ||
| Suitable for the identification of early genetic events leading to tumor formation | More genetically defined | |
Better discovery tool/uncovering mechanisms | Possible off-target effects need to be assessed | ||
Allows for targeted studies of well-known GBM mutations | Plasmid transduction efficiency issues | ||
Can address all possible trajectories of GBM formation | Requires validation of tumor presence | ||
| More focused study of extracellular matrix role | Does not mimic the human tumor microenvironment | |
Faster turnaround of results | No three-dimensional architecture | ||
Can incorporate novel elements of cell engineering | Interaction between tumorous and non-tumorous cell components not confirmed | ||
Easier to add additional cell types | Harder to accomplish fusion/infiltration |
